Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315). - Mandl A; Chen R; Das S; Strosberg JR; Kasi A; Konda B; Li D; Burns TF; Chauhan A; Ciombor KK; Dayyani F; Dorff T; et al. (The oncologist, 2026)